|
| 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)- Basic information |
Product Name: | 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)- | Synonyms: | 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)-;MBRI 001;MBRI-001;MBRI001. BPI-2358-d;NPI-2358-d;plinabulin-d | CAS: | 2054938-28-0 | MF: | C19H20N4O2 | MW: | 336.4 | EINECS: | | Product Categories: | | Mol File: | 2054938-28-0.mol | |
| 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)- Chemical Properties |
| 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)- Usage And Synthesis |
Description | MBRI-001 is a deuterium-substituted plinabulin derivative as a potent anti-cancer agent. MBRI-001 exhibited better pharmacokinetic characteristics than that of plinabulin. Additionally, its antitumor activity is in a low nanomolar level for a variety of cancer cell lines and high activity against human NCI-H460 xenograted in mice intravenous administration. Importantly, continuous administration of MBRI-001 exhibited lower toxicity compared to docetaxel. |
| 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene-d]-6-(phenylmethylene)-, (3Z,6Z)- Preparation Products And Raw materials |
|